NASDAQ: FEMYFemasys Inc Stock
$1.23+0.03 (+2.5%)
Updated Mar 24, 2023
FEMY Price
$1.23
Fair Value Price
N/A
Market Cap
$14.53M
52 Week Low
$0.57
52 Week High
$2.97
P/E
-1.56x
P/B
0.81x
P/S
10.89x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.23M
Earnings
-$10.86M
Gross Margin
65.7%
Operating Margin
-884.49%
Profit Margin
-886%
Debt to Equity
0.11
Operating Cash Flow
-$10M
Beta
0.97
Next Earnings
May 10, 2023
Ex-Dividend
N/A
Next Dividend
N/A
FEMY Overview
Femasys Inc., a biomedical company, offers surgical and non-surgical infertility products (FemaSeed, FemCerv, FemEMB) and permanent birth control solutions (FemBloc, FemChec) in the U.S. and internationally. Femasys offers its products to obstetrics-gynecological physicians, women's healthcare provider organizations, and reproductive endocrinologists. Femasys was incorporated in 2004 and is based in Suwanee, GA.
Zen Score
–
Industry Average (33)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how FEMY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FEMY is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FEMY is good value based on its book value relative to its share price (0.81x), compared to the US Medical Instruments & Supplies industry average (3.48x)
P/B vs Industry Valuation
FEMY is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more FEMY due diligence checks available for Premium users.
Be the first to know about important FEMY news, forecast changes, insider trades & much more!
FEMY News
Valuation
FEMY fair value
Fair Value of FEMY stock based on Discounted Cash Flow (DCF)
Price
$1.23
Fair Value
$2.60
Undervalued by
52.78%
FEMY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FEMY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.56x
Industry
23.41x
Market
21.37x
FEMY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.81x
Industry
3.48x
FEMY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FEMY's financial health
Profit margin
Revenue
$347.5k
Net Income
-$3.0M
Profit Margin
-858.5%
FEMY's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
FEMY's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$20.0M
Liabilities
$2.0M
Debt to equity
0.11
FEMY's short-term assets ($17.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FEMY's short-term assets ($17.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FEMY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.7M
Investing
-$18.5k
Financing
-$362.0k
FEMY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FEMY vs Medical Stocks
Femasys Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.